Brief Introduction

Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in the next generation antibody discovery and engineering, the company has advanced five candidates into late-stage clinical trials and one of which, QLETLI (格乐立), a biosimilar to adalimumab, is available to patients in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, including differentiated and innovative anti-OX40, anti-TIGIT antibodies.

Company Overview

Full name Bio-Thera Solutions,Ltd.
Abbreviations BIO-THERA
Code 688177
Founded 2003-7-28
Listing 2020-2-21
Domicile Guangzhou
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share -1.27 -2.96 /
R&D expenditure as a % of operating revenue 304.15% 90,930.15% /
Operating Revenue 184.99 0.70 0
Net Income -513.23 -1,022.62 -553.11

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 184.99 0.70 0
Operating Costs 744.95 1,037.69 568.63
Operating Income -513.62 -1,023.89 -553.33
Pretax Income -513.23 -1,022.62 -553.11
Income Tax 0 0 0
Net Income -513.23 -1,022.62 -553.11

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 1,467.17 177.84 217.35
Non-current Assets-Total 925.99 836.52 803.41
Total Assets 2,393.16 1,014.36 1,020.76
Current Liabilities-Total 385.36 380.48 213.22
Non-current Liabilities-Total 2.19 3.21 6.22
Total Liabilities 387.56 383.68 219.44
Stockholder's Equity
Share Capital 3,468.46 1,580.23 1,854.05
Retained Profits -1,462.86 -949.56 -1,052.72
Total Owners' Equity 2,005.60 630.67 801.32

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating -358.04 -597.98 -528.25
Net Cash Flows-Investing -1,177.45 -74.81 -339.34
Net Cash Flows-Financing 1,779.82 599.33 932.98

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
HEDYHOLDINGCO.,LTD 159.99 38.64%
Therabio International Limited 47.18 11.39%
广州启奥兴投资合伙企业 23.17 5.6%
珠海吉富启恒医药投资合伙企业 21.56 5.21%
广州中科粤创三号创业投资合伙企业 21.33 5.15%
广州兴昱投资合伙企业 21.32 5.15%
广州晟昱投资合伙企业 16.00 3.86%
广州市浥尘投资企业 10.74 2.59%
广州返湾湖投资合伙企业 7.42 1.79%
LISHENGFENG 6.52 1.57%
31 Dec 2020

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.